[7] Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Rad Biol Med. 1991; 10: 339–352.
[8] Khan S, Rupp J. The effect of exercise conditioning, diet and drug therapy on glycosylated hemoglobin levels in type 2 (NIDDM) diabetics. J Sports Med Phys Fitness. 1995; 35: 281–288.
[9] Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S, et al. Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes. 1991; 40: 52–57.
[10] Meloni T, Pacifico A, Forteleoni G, Meloni GF. HbA1c levels in diabetic Sardinian patients with or without G6PD deficiency. Diabetes Res Clin Pract. 1994; 23(1): 59–61.
[11] Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995; 18(4): 440–447.
[12] Broussolle C, Tricot F, Garcia I, Orgiazzi J, Revol A. Evaluation of the fructosamine test in obesity: Consequences for the assessment of past glycemic control in diabetes. Clin Biochem. 1991; 24: 203–209.
[13] Guillasseau PJ, Charles MA, Godard V, Timsit J, Chanson P, Paolaggi F, Peynet J, Eschwege E, Rousselet F, Lubetzki J. Comparison of fructosamine with glycated “hemoglobin as an index of glycemic control in diabetic patients. Diabetes Res. 1990; 13: 127–131.
[14] Knecht KJ, Dunn JA, McFarland KF, et al. Effect of diabetes and aging on carboxymethyllysine levels in human urine. Diabetes. 1991; 40: 190–196.
[15] Giugliano D, Ceriello A, Paolisso G. Diabetes mellitus, hypertension, and car diovascular disease: Which role for oxidative stress? Metabolism. 1995; 44(3): 363–368.
[16] Dills WL. Protein fructosylation: Fructose and the Maillard reaction. Am J Clin Nutr. 1993; 58(Suppl): 779S–787S.
[17] Yaylayan VA. Classification of the Maillard reaction: A conceptual approach. Trends Food Sci Technol. 1997; 8(1): 13–18.
[18] Rattan SI. Synthesis, modifications, and turnover of proteins during aging. Exp Gerontol. 1996; 31(1/2): 33–47.
[19] Rattan SI, Derventzi A, Clark BF. Protein synthesis, post-translational modifications, and aging. Ann N Y Acad Sci. 1997; 663: 48–62.
[20] Kimura T, Ikeda K, Takamatsu J, Miyata T, Sobue G, Miyakawa T, Horiuchi S. Identification of advanced glycation end products of the Maillard reaction in Pick’s disease. Neurosci Lett. 1996; 219: 95–98.
[21] Coufturier M, Amman H, Des Rosiers C, Comtois R. Variable glycation of serum proteins in patients with diabetes mellitus. Clin Invest Med. 1997; 20(2): 103–109.
[22] Coussons PJ, Jacoby J, McKay A, Kelly SM, Price NC, Hunt JV. Glucose modification of human serum albumin: A structural study. Free Rad Biol Med. 1997; 22(7): 1217–1227.
[23] Suarez G, Maturana J, Oronsky AL, Raventos-Suarez C. Fructose-induced fluorescence generation of reductively methylated glycated bovine serum albumin: Evidence for nonenzymatic glycation of Amadori adducts. Biochim Biophys Acta. 1991; 1075(1): 12–19.
[24] Wu JT, Tu MC, Zhung P. Advanced glycation end product (AGE): Characterization of the products from the reaction between D-glucose and serum albumin. J Clin Lab Analysis. 1996; 10(1): 21–34.
[25] Miyata T, Hori O, Zhang JH, Yan SD, Ferran L, Iida Y, Schmidt AM. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-β2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J Clin Invest. 1996; 98(5): 1088–1094.
[26] Wolff SP, Bascal ZA, Hunt JV. “Autooxidative glycosylation”: Free radicals and glycation theory. Prog Clin Bio Res. 1989; 304: 259–275.
[27] Lapolla A, Poli T, Valerio A, Fedele D. Glycosylated serum proteins in diabetic patients and their relation to metabolic parameters. Diabete Metabolisme. 1985; 11: 238–242.
[28] Ballou SP, Lozanski GB, Hodder S, Rzewnicki DL, Mion LC, Sipe JD, Ford AB, Kushner I. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Aging. 1996; 25: 224–230.
[29] Cooper GJ, Tse CA. Amylin, amyloid and age-related disease. Drugs Aging. 1996; 9(3): 202–212.
[30] Hilliquin P. Biological markers in inflammatory rheumatic diseases. Cell Mol Biol. 1995; 41(8): 993–1006.
[31] Rook GA, Zumia A. Gulf War syndrome: Is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet. 1997; 349: 1831–1833.
[32] Chandra RK. Nutrition and the immune system: An introduction. Am J Clin Nutr. 1997; 66(2): 460S–463S.
[33] Sprietsma JE. Zinc-controlled Th1/Th2 switch significantly determines development of diseases. Med Hypotheses. 1997; 49(1): 1–14.
[34] Mendall MA, Patel R, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ. 1996; 312(1038): 1061–1065.
[35] Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997; 349(9050): 462–466.
[36] Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989; 30: 39–49.
[37] Hasdai D, Scheinowitz M, Leibovitz E, Sclarovsky S, Eldar M, Barak V. Increased serum concentrations of interleukin-1b in patients with coronary artery disease. Heart. 1996; 76(1): 24–28.
[38] Pelletier JP, Martel-Pelletier J. [Role of synovial inflammation, cytokines and IGF-1 in the physiopathology of osteoarthritis.] Rev Rhum Ed Fr. 1994; 61(9, pt 2): 103S–108S.
[39] Moulton PJ. Inflammatory joint disease: The role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci. 1996; 53(4): 317–324.
[40] Kaufman W. Niacinamide therapy for joint mobility: Therapeutic reversal of a common clinical manifestation of the normal aging process. Conn State Med J. 1953; 17: 584–589.
[41] Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: Pilot study. Inflamm Res. 1996; 45(1): 330–334.
[42] Miesel R, Kurpisz M, Kroger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. Inflammation. 1995; 19(3): 379–387.
[43] Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of α-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung. 1992; 42(6): 829–831.
[44] Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med. 1997; 337(3): 195–197.
[45] Clancy RM, Abramson SB. Nitric oxide: A novel mediator of inflammation. Proc Soc Exp Biol Med. 1995; 210(2): 93–101.
[46] Goodman J. Histone tails wag the DNA dog. Helix. [University of VA Health System]. Spring 2000; 17(1).
2
Theories of Aging
Old and New Concepts of the Aging Process
Vincent C. Giampapa, M.D., F.A.C.S.
Stanley Burzynski, M.D., Ph.D.
Ronald Pero, Ph.D.
Errors,